II.b
ARDS - Acute lung injury
(Fr: SDRA sur critères gazométriques PaO2/FIO2). May overlap with Ia. Mechanical ventilation commonly needed. ECMO required in some instances (PMID 29967877). ARDS definition and grading at PMID 22797452. ARDS (and formerly ALI) are defined on the basis of gas exchange abnormalities. Thus, ARDS is not a well-characterized disease entity and may arise in widely disparate clinical scenarios. Pathologically, ARDS may correspond to DAD, pulmonary edema, acute NSIP-like ILD w/wo granulomas, -eosinophilic pneumonia (AEP), AFOP, amiodarone pulmonary toxicity, DAH, fat or silicone embolism, AIP, radiation injury, pulmonary fibrosis exacerbated by drugs or surgery (see under specific patterns) and drug- or alcohol-induced aspiration pneumonitis (see under XIg). Appropriate tests and BAL help exclude an infection and separate these entities. Some patients respond to intravenous corticosteroid therapy. Review at PMID 1939859. See also under IL 'Diffuse Alveolar Damage', XIg, XVf and under 'Postoperative ARDS'
Causative drugs
Quinine
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.j II - Pulmonary edema - Acute lung injury - ARDS
II.j - Transient pulmonary opacities/infiltrates (see also under Iav) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) III.m III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.m - Coagulopathy VIII.b VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.b - Hematoma of/around central airway wall potentially causing UAO VIII.d VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.d - Thermal (burns, frostbite), chemical or caustic facial and/or airway injury X.a X - Systemic/Distant conditions, syndromes and reactions
X.a - DRES syndrome - DRESS-like reaction X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.h X - Systemic/Distant conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.m X - Systemic/Distant conditions, syndromes and reactions
X.m - Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative) X.ad X - Systemic/Distant conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis X.af X - Systemic/Distant conditions, syndromes and reactions
X.af - Thrombotic microangiopathy XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XIV.a XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.a - Methemoglobinemia XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
Radiation therapy (early effects)
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis I.ab I - Interstitial/parenchymal lung disease
I.ab - Radiation-induced lung injury (RILI) I.ac I - Interstitial/parenchymal lung disease
I.ac - Acute radiation pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
Radiation therapy (medium term & late effects)
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis IV.h IV - Airway involvement
IV.h - Large airway necrosis IV.k IV - Airway involvement
IV.k - Bronchiectasis IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax V.l V - Pleural and/or pericardial involvement
V.l - Malignant pleural mesothelioma V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) V.t V - Pleural and/or pericardial involvement
V.t - The apical cap VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.t VI - Pulmonary vasculopathies
VI.t - Pulmonary artery aneurysm(s) VI.ab VI - Pulmonary vasculopathies
VI.ab - Pulmonary artery stenosis VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis VII.i VII - Mediastinal involvement
VII.i - Mediastinitis VII.j VII - Mediastinal involvement
VII.j - Compression of mediastinal structures/organs VII.l VII - Mediastinal involvement
VII.l - Calcification of mediastinal lymph nodes VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.j VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.j - Laryngeal disorder: dysphonia, hoarseness VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) XI.g XI - Miscellaneous
XI.g - Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility) XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula) XI.i XI - Miscellaneous
XI.i - Esophageal toxicity XI.p XI - Miscellaneous
XI.p - Chest deformity: platythorax XI.v XI - Miscellaneous
XI.v - Rib fracture XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XI.ax XI - Miscellaneous
XI.ax - Esophageal stenosis/stricture XI.bb XI - Miscellaneous
XI.bb - Aorto-esophageal fistula XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ad XII - Cardiovascular involvement / toxicity
XII.ad - Effusive-constrictive pericarditis XII.ak XII - Cardiovascular involvement / toxicity
XII.ak - Late left ventricular dysfunction/failure XII.an XII - Cardiovascular involvement / toxicity
XII.an - Pericardial calcification XII.bc XII - Cardiovascular involvement / toxicity
XII.bc - Coarctation of the aorta (acquired) XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial) XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer XIII.j XIII - Neoplastic conditions
XIII.j - Pulmonary synovial sarcoma XIII.l XIII - Neoplastic conditions
XIII.l - Chondrosarcoma XIII.m XIII - Neoplastic conditions
XIII.m - Tumor of the heart XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.bi XVI - Imaging
XVI.bi - Imaging: Hyperlucent lung XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
Radiation therapy to the chest
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.h III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.h - Major/massive hemoptysis IV.h IV - Airway involvement
IV.h - Large airway necrosis IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.h V - Pleural and/or pericardial involvement
V.h - Chylothorax V.k V - Pleural and/or pericardial involvement
V.k - Pleural calcifications VI.c VI - Pulmonary vasculopathies
VI.c - Pulmonary veno-occlusive disease VI.x VI - Pulmonary vasculopathies
VI.x - Pulmonary lymphangiectasis VII.d VII - Mediastinal involvement
VII.d - Fibrosing mediastinitis VIII.c VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.r VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.r - Tracheal/large airway necrosis, chondronecrosis, perforation VIII.t VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.t - Vocal cord paresis/paralysis VIII.ab VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.ab - Airway (e.g. tracheoesophageal) fistula IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.h XI - Miscellaneous
XI.h - Esophageal pathology (erosion, ulcer, tear, rupture, fistula) XI.i XI - Miscellaneous
XI.i - Esophageal toxicity XI.j XI - Miscellaneous
XI.j - Esophageal dysmotility XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction XII.k XII - Cardiovascular involvement / toxicity
XII.k - Constrictive pericarditis - Pericardial thickening XII.o XII - Cardiovascular involvement / toxicity
XII.o - Coronary artery disease (subacute, chronic) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XIII.e XIII - Neoplastic conditions
XIII.e - Breast cancer XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.bm XV - Pathology
XV.bm - Path: Diffuse lymphangiectasis XVI.bl XVI - Imaging
XVI.bl - Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis) XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
Radiation therapy, infusional (injected 131I or 90Y radioactivity)
I.b - Pneumonitis (ILD) I.o I - Interstitial/parenchymal lung disease
I.o - Focal/localized area of pneumonitis/fibrosis I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.ab I - Interstitial/parenchymal lung disease
I.ab - Radiation-induced lung injury (RILI) I.ac I - Interstitial/parenchymal lung disease
I.ac - Acute radiation pneumonitis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
Radiocontrast media (RCM)
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia (subacute, acute) I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.h II - Pulmonary edema - Acute lung injury - ARDS
II.h - Overload pulmonary edema (including posttransfusional (TACO)) II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.b IV - Airway involvement
IV.b - Bronchospasm and angioedema IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) VI.e VI - Pulmonary vasculopathies
VI.e - Fat/oil embolism - The FES embolism syndrome VI.aa VI - Pulmonary vasculopathies
VI.aa - Lipiodol pulmonary embolism X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) X.ap X - Systemic/Distant conditions, syndromes and reactions
X.ap - Delayed anaphylaxis XVIII.h XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.h - Eye-catcher: Lipiodol embolism
Ricin (Castor oil)
II.b - ARDS - Acute lung injury X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
Rifampicin
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
Rituximab
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx) IV.d IV - Airway involvement
IV.d - Cough (lone) IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.j IV - Airway involvement
IV.j - Bronchiolitis (a clinical-imaging pattern suggestive of) IV.k IV - Airway involvement
IV.k - Bronchiectasis VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma VIII.x VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.x - Opportunistic large airway infection (bacterial, fungal, viral) IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction/damage IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome (w/wo ARF) X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive X.ao X - Systemic/Distant conditions, syndromes and reactions
X.ao - Flare of preexisting vasculitis XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic) XII.g XII - Cardiovascular involvement / toxicity
XII.g - Coronary artery disease (acute) - Myocardial ischemia/infarction XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XXI.c XXI - Rechallenge data
XXI.c - Tolerance can be induced successfully starting with minute dosage
Rofecoxib
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal)
Ruxolitinib
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension IX.h IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.h - Dyspnea, unexplained otherwise X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) X.al X - Systemic/Distant conditions, syndromes and reactions
X.al - Drug withdrawal syndrome XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus pulmonary and/or systemic infection
Sevoflurane
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) VIII.k VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.k - Airway fire/explosion XIV.c XIV - Hemoglobinopathies - Abnormal hemoglobin states (acquired)
XIV.c - Carboxyhemoglobinemia
Silicone, fluid
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation I.al I - Interstitial/parenchymal lung disease
I.al - Silicone pneumonitis - 'Silicone lung' II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.u II - Pulmonary edema - Acute lung injury - ARDS
II.u - Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) VI.m VI - Pulmonary vasculopathies
VI.m - Silicone pulmonary embolism (SE) - SE syndrome VII.k VII - Mediastinal involvement
VII.k - Mediastinal silicone infiltration/siliconoma VIII.k VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.k - Submucosal airway petechiae/hemorrhage X.u X - Systemic/Distant conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Chest pain (acute or subacute), lone or prominent XI.aa XI - Miscellaneous
XI.aa - CNS symptoms or involvement, stroke XI.bn XI - Miscellaneous
XI.bn - A restrictive lung function defect XI.bo XI - Miscellaneous
XI.bo - Parietal chest involvement XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.l XV - Pathology
XV.l - Path: Pulmonary fibrosis (not otherwise specified or unclassifiable) XV.bn XV - Pathology
XV.bn - Path: Silicone droplets/vacuoles in lung tissue, pulmonary vasculature, or lymph nodes XV.bo XV - Pathology
XV.bo - Path: Siliconoma XV.cw XV - Pathology
XV.cw - Path: Silicone pulmonary embolism XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution XVI.ax XVI - Imaging
XVI.ax - Imaging: Foreign body pulmonary embolism XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy XIX.d XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.d - BAL: Gross or microscopic bleeding/hemorrhage XIX.l XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.l - BAL: Silicone globules in macrophages
Sirolimus
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH) IV.d IV - Airway involvement
IV.d - Cough (lone) IV.l IV - Airway involvement
IV.l - Bronchial stump dehiscence V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VI.f VI - Pulmonary vasculopathies
VI.f - Hemolytic and uremic syndrome (HUS). See also under Xaf VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) X.c X - Systemic/Distant conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.m XV - Pathology
XV.m - Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern) XV.n XV - Pathology
XV.n - Path: Pulmonary alveolar proteinosis pattern (PAP pattern) XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis XV.bf XV - Pathology
XV.bf - Path: Pulmonary necrotizing granuloma or granulomas XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
Snake envenoming
II.b - ARDS - Acute lung injury II.q II - Pulmonary edema - Acute lung injury - ARDS
II.q - Respiratory distress or failure, not otherwise specified V.e V - Pleural and/or pericardial involvement
V.e - Hemothorax - Serosanguineous pleural effusion XXIV.d XXIV - Veterinary medicine
XXIV.d - Veterinary: Pulmonary bleeding (hemoptysis, alveolar hemorrhage)
Sorafenib
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax X.n X - Systemic/Distant conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS) XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
Stem cell infusion/transplantation
II.b - ARDS - Acute lung injury II.e II - Pulmonary edema - Acute lung injury - ARDS
II.e - Transfusion-related acute lung injury (TRALI) (May cause ARDS) III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage, diffuse (DAH)